Aeon raises EUR €8.2 million to expand AI-driven health checks

Swiss health technology company Aeon has secured EUR €8.2 million in seed funding as it expands its AI-driven early detection and preventive healthcare platform.

The investment round was led by London-based venture capital firm Concentric, with participation from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR, and Swiss investor Daniel Gutenberg. With plans to open more than 10 new locations in the coming months, Aeon is positioning itself to expand across Switzerland, Germany, the UK, and additional international markets.

Aeon's platform differentiates itself from other consumer health offerings by combining full-body MRI scans, advanced blood biomarker testing, and genetic screening into a single, one-hour check-up. This integrated approach enables the early detection and prediction of over 500 health risks, with findings reviewed by board-certified physicians and discussed directly with a radiologist.

The company reports that, to date, its clinical-grade follow-up process has resulted in a 0% false positive rate, which it describes as a significant point of distinction in an industry where overdiagnosis and unnecessary interventions can be common.

Technology and features

Aeon utilises artificial intelligence in three core capacities. Firstly, it automates imaging analysis by detecting and quantifying anomalies on MRI scans, improving both speed and consistency of clinical assessments. Secondly, it uses cross-validation techniques to correlate MRI findings with blood and genetic data, which aims to reduce false positive rates and enhance clinical specificity. Thirdly, Aeon's predictive modelling generates personalised risk profiles for each user, estimating likelihoods for more than 500 conditions and informing targeted prevention strategies.

According to figures from the Global Alliance for Chronic Diseases, 41 million people die each year from non-communicable diseases, with this number projected to rise by 27% by 2030. Despite evidence suggesting that around 80% of these deaths are preventable, challenges persist due to fragmented healthcare data and slow systemic responses.

The company has already reported impact in its home market since launching in 2024. Aeon recounts cases where early-stage cancers, aneurysms, Alzheimer's disease, and other critical conditions were detected in individuals who showed no noticeable symptoms. The company highlighted an incident involving a 56-year-old man whose previously undetected kidney cancer was found during a scan, facilitating timely surgical intervention.

Insurance integration

Aeon is also the first company to offer full-body preventive check-ups that are eligible for insurance reimbursement. Agreements with Switzerland's largest health insurers, including KPT, enable customers to recover up to 80 percent of the cost depending on their insurance plan. The company describes this as setting a precedent for broader access to preventative health services.

The latest funding will be directed toward expanding Aeon's presence within Switzerland and into new European markets, as well as accelerating collaborations with insurers and employers to increase uptake and affordability of its service. In tandem, the company aims to further develop its multi-modal AI platform to support earlier and more precise diagnoses at scale.

Leadership and background

Aeon's founding team consists of Chief Executive Officer Tim Seithe, former founder of Tillhub which was sold to Unzer in 2022, and Chief Product Officer Samuel Frey, who previously led product initiatives at diagnostics firm Platomics. Scientific advice is provided by Dr Andreas Lemke, an MRI physicist and founder of brain imaging diagnostics company Mediaire.

Tim Seithe, Aeon's founder and CEO, commented:

"We're redefining preventive care by shifting it from reactive checks to proactive, personalised health management. Our approach goes beyond early disease detection — we're tackling one of preventive medicine's biggest challenges: false positives. Every customer receives a tailored risk profile, along with a clear, medically grounded plan to monitor and reduce their health risks over time."

Commenting on the investment, Alex Stroud, Principal at Concentric, said:

"Aeon is not just another testing solution. In our view, many consumer health products on the market today deliver questionable value. Validated by insurers, Aeon is delivering the most medically robust preventive health product on the market. That rare combination of clinical rigor and commercial scalability is what makes this team so exciting."